denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Education, Diseases, Myeloid Malignancies
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Education, Diseases, Myeloid Malignancies
Friday, December 6, 2024: 3:00 PM-6:00 PM
Seaport Ballroom ABCD
(Manchester Grand Hyatt San Diego)
Chair:
Eytan M. Stein, MD, Memorial Sloan-Kettering Cancer Center
Disclosures:
Stein: Jazz Pharmaceuticals: Consultancy, Other: consulting fees; Daiichi Sankyo, Inc.: Consultancy, Other: consulting fees; Agios Pharmaceuticals: Consultancy, Other: consulting fees; Servier: Consultancy, Other: consulting fees; Abbvie: Consultancy, Other: consulting fees; Astellas Pharmaceuticals: Consultancy, Other: consulting fees; Celgene: Consultancy, Other: consulting fees; AstraZeneca: Consultancy, Other: consulting fees; Gilead: Consultancy, Other: consulting fees; Genentech: Consultancy, Other: consulting fees.
Speakers:
Alexander E. Perl, MD, University of Pennsylvania
,
Richard M. Stone, MD, Dana-Farber Cancer Institute
,
Andrew H Wei, MBBS, PhD, FRACP, FRCPA, Peter MacCallum Cancer Centre
and
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center
Disclosures:
Perl: Astellas: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: grant, consulting fees, Research Funding; Rigel Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees; Aptose Biosciences: Membership on an entity's Board of Directors or advisory committees; Schrödinger,: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo, Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: grant, consulting fees; Syndax Pharmaceuticals, Inc.: Other: grant, Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: grant, consulting fees, Research Funding; Syndax: Membership on an entity's Board of Directors or advisory committees, Research Funding; Curis: Membership on an entity's Board of Directors or advisory committees; ImmunoGen: Membership on an entity's Board of Directors or advisory committees; Foghorn: Consultancy; BeatAML, LLC: Other: DSMC member. Stone: LAVA Therapeutics: Consultancy, Other: consulting fees; Syntrix Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consulting fees; Syros Pharmaceuticals: Consultancy, Other: consulting fees; Kura Oncology: Consultancy, Other: consulting fees; Jazz Pharmaceuticals: Consultancy, Other: consulting fees; GSK: Consultancy, Other: consulting fees; DAVA Oncology: Consultancy, Other: consulting fees; Boston Scientific: Consultancy, Other: consulting fees; Bristol Myers Squibb: Consultancy, Other: consulting fees; BerGenBio: Consultancy, Other: consulting fees; AvenCell: Consultancy, Other: consulting fees; Amgen: Consultancy, Other: consulting fees; CTI BioPharma: Consultancy, Other: consulting fees; Hemavant Sciences: Consultancy, Other: consulting fees; Aptevo Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consulting fees; Janssen: Consultancy, Other: consulting fees; AROG Pharmaceuticals: Consultancy, Other: consulting fees; AbbVie: Consultancy, Other: consulting fees; Epizyme Inc: Consultancy, Other: consulting fees; Ligand Pharmaceuticals: Consultancy, Other: consulting fees; Celularity: Consultancy, Other: consulting fees; Actinium Pharmaceuticals, Inc.,: Consultancy, Other: consulting fees; Takeda Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consulting fees; Rigel Therapeutics, Inc.: Consultancy, Other: consulting fees; Novartis: Consultancy, Other: consulting fees. Wei: AbbVie Inc, Astellas, Bristol Myers Squibb, Novartis, Servier Pharmaceuticals LLC: Speakers Bureau; AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals: Research Funding; Servier Pharmaceuticals LLC, Shoreline Biosciences: Consultancy; AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Gilead Sciences Inc, Janssen Biotech Inc, MacroGenics Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Shoreli: Membership on an entity's Board of Directors or advisory committees. Wang: Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Schrodinger: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Membership on an entity's Board of Directors or advisory committees; NuProbe: Consultancy, Membership on an entity's Board of Directors or advisory committees; UptoDate: Other: Section Editor; Amgen: Membership on an entity's Board of Directors or advisory committees; Immunogen: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; Qiagen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; J&J: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Speakers Bureau; Sellas: Membership on an entity's Board of Directors or advisory committees; Mana: Membership on an entity's Board of Directors or advisory committees; Kura: Speakers Bureau; Dava Oncology: Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Award Committee, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Research Funding, Speakers Bureau.
The enduring CME-accredited video/audio recorded proceedings from this activity will be made available in mid/late January 2025. Visit the Research To Practice website for more information (www.ResearchToPractice.com).
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with Acute Myeloid Leukemia (AML). Five clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of AML. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.
See more of: Friday Satellite Symposia